



UNITED STATES PATENT AND TRADEMARK OFFICE

MAR 15 2011

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Donald J. Bird
Morgan Lewis & Bockius LLP
1111 Pennsylvania Ave., N.W.
Washington DC 20004

Re: Patent Term Extension
Application for
U.S. Patent No. 5,434,171

WITHDRAWAL OF APPLICATION FOR PATENT TERM EXTENSION

This is in response to the "Express Election of Application for Extension of Patent Term," filed January 20, 2011, of the application for patent term extension for U.S. Patent No. 5,250,542, (ENTEREG® (alvimopan)).

Because U.S. Patent No. 5,250,542 was elected for extension pursuant to 37 C.F.R. 1.785, the present application for extension of U.S. Patent No. 5,434,171 is hereby withdrawn and the application is dismissed. Furthermore, the clarification on the extended term of U.S. Patent No. 5,434,171, had it been elected, is acknowledged.

Any correspondence with respect to this matter should be addressed as follows:

By mail: Mail Stop Hatch-Waxman PTE
P.O. Box 1450
Alexandria, VA 22313-1450

By FAX: (571) 273-0100

Telephone inquiries related to this determination should be directed to the undersigned at (571) 272-7755. E-mail inquiries should be directed to mary.till@uspto.gov.

Mary C. Till
Legal Advisor
Office of Patent Legal Administration
Office of the Associate Commissioner
for Patent Examination Policy

cc: Office of Regulatory Policy
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, Rm. 6222
Silver Spring, MD 20993-0002

RE: ENTEREG® (alvimopan)
Docket No.: FDA-2009-E-0015

Attention: Beverly Friedman